ro7234292
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Nov 27, 2017 (NCT03342053)
Timeline
Indications
Studied for
Mechanism of action
- HuntingtinINHIBITOR
HTT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05686551 | Phase 2 | Feb 3, 2023 | Roche |
| NCT04000594 | Phase 1 | Jul 17, 2019 | Roche |
| NCT03842969 | Phase 3 | Apr 23, 2019 | Roche |
| NCT03761849 | Phase 3 | Jan 23, 2019 | Roche |
| NCT03342053 | Phase 2 | Nov 27, 2017 | Ionis Pharmaceuticals, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 4 | 4 | 3 | 2019 |
| Ionis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1